| Literature DB >> 30213136 |
Abstract
As an important second messenger, the calcium ion (Ca2+) plays a vital role in normal brain function and in the pathophysiological process of different neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and epilepsy. Ca2+ takes part in the regulation of neuronal excitability, and the imbalance of intracellular Ca2+ is a trigger factor for the occurrence of epilepsy. Several anti-epileptic drugs target voltage-dependent calcium channels (VDCCs). Intracellular Ca2+ levels are mainly controlled by VDCCs located in the plasma membrane, the calcium-binding proteins (CBPs) inside the cytoplasm, calcium channels located on the intracellular calcium store (particular the endoplasmic reticulum/sarcoplasmic reticulum), and the Ca2+-pumps located in the plasma membrane and intracellular calcium store. So far, while many studies have established the relationship between calcium control factors and epilepsy, the mechanism of various Ca2+ regulatory factors in epileptogenesis is still unknown. In this paper, we reviewed the function, distribution, and alteration of VDCCs and CBPs in the central nervous system in the pathological process of epilepsy. The interaction of VDCCs with CBPs in the pathological process of epilepsy was also summarized. We hope this review can provide some clues for better understanding the mechanism of epileptogenesis, and for the development of new anti-epileptic drugs targeting on VDCCs and CBPs.Entities:
Keywords: calcium binding proteins (CBPs); epilepsy; voltage-dependent calcium channels (VDCCs)
Mesh:
Substances:
Year: 2018 PMID: 30213136 PMCID: PMC6164075 DOI: 10.3390/ijms19092735
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
The distribution, physiological function, and possible roles of voltage-dependent calcium channels (VDCCs) in the pathological process of epilepsy.
| VDCCs | Physiological Function | Possible Roles in Pathological Process of Epilepsy |
|---|---|---|
| L-Type | Shape neuronal firing and activate Ca2+-dependent pathways involved in the control of gene expression, and support neuronal plasticity [ | Control neuronal excitability and likely provide the gene basis of epileptogenesis through regulation of gene expression |
| P/Q-Type | Regulate neurotransmitter release [ | Inhibit epileptogenesis based on the fact that its null mutation can cause the occurrence of absence epilepsy |
| N-Type | Regulate neurotransmitter release [ | Inhibit neuronal excitability through fast redistribution in the subcellullar organs of neurons |
| R-Type | Regulate long-term potentiation (LTP) and neurotransmitter release [ | Trigger epileptiform activity in neuronal populations and promote epileptogenesis |
| T-Type | Regulate rhythmic firing of neurons [ | Control burst firing of action potentials of neurons, and the plasticity of neurons induced by epiletogenic factors and promote the formation of epileptogenic focus |
The regional, cellular, and subcellular distribution of VDCCs in the nervous system.
| VDCCs | Regional and Cellular Distribution | Subcellular Distribution |
|---|---|---|
| L-Type | Cav1.1 and Cav1.4 are expressed in a limited subset of neurons in the brain [ | Located postsynaptically, predominantly in the soma, dendritic spines, and shafts of dendrites [ |
| P/Q-Type | Expressed in hippocampal principal cells of the human [ | Widely expressed at the presynaptic terminals [ |
| N-Type | Expressed in the dorsal cortex and the hippocampal formation of rats [ | Localized in the dendrites, presynaptic membrane, and nucleus |
| R-Type | Expressed in the most basal ganglia regions, the thalamus, hypothalamus, amygdala, hippocampus, and cortex [ | Localized in the presynaptic membrane [ |
| T-Type | Present in neurons in both the central and peripheral nerve system | Localized in both soma and dendrites [ |
The alterations of L-type VDCCs in the animal epileptic models and patients with temporal lobe epilepsy (TLE).
| L-Type VDCCs | Epileptic Animal Model | Patients with TLE |
|---|---|---|
|
| Increased in the somata of the pyramidal cells and granule cells in the KA rat model [ | Increased in the astrocytes in Ammon’s horn (or hippocampal) sclerosis (AHS) specimens [ |
| Decreased in the neuropil of the CA3 stratum pyramidale and the part of CA1 regions in the KA rat model [ | Decreased in the dentate gyrus granule cells and in the residual CA3 pyramidal neurons [ | |
| No changes in the hippocampal subareas in the kindling model [ | ||
|
| Increased in the hippocampal subareas in the kindling model [ | Increased in the neuropil of molecular layer of the dentate gyrus [ |
| Decreased in CA3 and the hilus of the dentate gyrus of the KA rat model [ |
The alterations of N- and R-type VDCCs in the pathological process of epilepsy and the effect of gene knockout.
| VDCCs | Epileptic Animal Model | Patients with TLE | Gene Knockout Outcomes |
|---|---|---|---|
|
| Increased in the dendritic fields of CA1 and CA3 areas of hippocampus in the rat kindling model [ | Increased in the molecular layer [ | Knockout mice displayed hyperactivity and vigilance state [ |
| Decreased in the stratum lucidum of CA3 of the KA rat model [ | |||
| No changes in CA1 neurons in the mouse pilocarpine model [ | |||
|
| Increased in the inferior colliculus neurons of seizure-naïve rats [ | Increased in the molecular layer of the dentate gyrus [ | Knockout mice show hippocampal seizure resistance and reduced neuronal excitotoxicity [ |
| Decreased in both cerebellum and medulla of genetic absence epilepsy rats from Strasbourg (GAERS) [ |
Alterations of P/Q- and T-type VDCCs in the pathological process of epilepsy, and gene interference, mutation, and knockout outcomes.
| VDCCs | Alterations in the Pathological Process of Epilepsy | Gene Interference, Mutation and Knockout Outcomes |
|---|---|---|
|
| Increased in the molecular layer of the dentate gyrus of patient with TLE [ | Gene null mice exhibit ataxia and absence seizures [ |
| Decreased in CA3 and the hilus of dentate gyrus of the rat KA model [ | ||
| No change in the cerebellum of the rat KA model (6 h, 24 h and 7 days after KA treatment) [ | ||
|
| Increased in the reticular thalamic neurons of GAERS rats [ | Knockout mice did not show the burst firing of action potentials and were resistant to baclofen-induced seizures [ |
|
| Increased in both messenger RNA (mRNA) and protein level in the hippocampal CA1 area in the mouse pilocarpine model [ | Mutation has been associated with seizure disorders, autism, and hyperaldosteronism [ |
Figure 1Schematic representation to show the role of calcium-binding proteins (CBPs) in the pathological process of epilepsy. The green pathways show the inhibitory role of CBPs, which may down-regulate neuronal excitability and prevent the pathological process of epilepsy; the red pathways show the excitatory role of CBPs, which likely increase neuronal excitability and promote the pathological process of epilepsy. Calmodulin (CaM) can exert inhibitory functions through three pathways, including 1. binding to intracellular C-terminal domains (CTDs) of voltage-gated Na+ channel (Nav) and limit persistent Na+ current and accelerate inactivation across the Nav family (inhibit Na+ influx); 2. activation of the KCNQ2 channel (promote K+ efflux); 3. down-regulating intracellular Ca2+ through a buffering function, CaMK II media, and regulating VDCCs via Ca2+-dependent inactivation (CDI). calbindin (CB), parvulbumin (PV), and calretinin (CR) all can reduce intracellular Ca2+ through their buffering functions. In addition, PV and CR offer an inhibitory effect through regulating Gamma-amino butyric acid (GABA) release and synchronizing inhibitory interneurons respectively. CaM and CB can increase neuronal excitability by elevating intracellular Ca2+ via Ca2+-dependent facilitation (CDF) and the CDI of VDCCs respectively. CR can exert an excitatory effect through both CDF and CDI of VDCCs. In addition, CR may facilitate the pathological process of epilepsy through promoting neuronal axonal sprouting and impaired circuitry formation in the epileptic focus. (+) and (−) indicate promoting and inhibiting effects, respectively. (↑) and (↓) in the textbox indicate increase and decrease respectively. Arrows outside the textbox indicate the pathways.